S Bank Fund Management Ltd Makes New $303,000 Investment in IQVIA Holdings Inc. $IQV

Key Points

• S Bank Fund Management Ltd has acquired a new stake in IQVIA Holdings Inc, purchasing 1,721 shares valued at approximately $303,000.
• Multiple institutional investors, including Brighton Jones LLC and Marshall Wace LLP, have significantly increased their positions in IQVIA, indicating strong interest in the company.
• Analysts project a consensus price target of $228.62 for IQVIA, and the stock holds a "Moderate Buy" rating based on various analyst evaluations.

S Bank Fund Management Ltd purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,721 shares of the medical research company's stock, valued at approximately $303,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. American National Bank & Trust bought a new position in IQVIA in the 1st quarter valued at $26,000. Clal Insurance Enterprises Holdings Ltd grew its position in IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after acquiring an additional 131 shares during the last quarter. Golden State Wealth Management LLC grew its position in IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after acquiring an additional 130 shares during the last quarter. AllSquare Wealth Management LLC bought a new position in IQVIA in the 1st quarter valued at $33,000. Finally, ST Germain D J Co. Inc. grew its position in IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Price Performance

Shares of IQV traded up $1.49 during mid-day trading on Monday, hitting $192.58. The company's stock had a trading volume of 1,341,034 shares, compared to its average volume of 1,984,722. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The firm has a 50-day simple moving average of $170.40 and a 200 day simple moving average of $168.40. The firm has a market capitalization of $32.74 billion, a P/E ratio of 27.87, a P/E/G ratio of 2.10 and a beta of 1.30. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The company's quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the firm earned $2.64 EPS. Analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Truist Financial upped their price objective on IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Redburn Partners set a $188.00 price target on IQVIA in a research report on Friday, May 23rd. Barclays increased their price target on IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. Finally, Mizuho increased their price target on IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Seven analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $228.62.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares of the company's stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider directly owned 2,910 shares of the company's stock, valued at $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.